A pipeline built from human evidence.

Our lead cardiovascular asset

The program began with a child whose rare genetic mutation exposed the mechanism driving her disease with unusual clarity. The platform matched that mechanism to an existing approved medicine. Following treatment, objective clinical improvement was observed over 18 months, and the case is peer-reviewed and published. Animal work supported the same mechanism in a broader population, and that program has now cleared preclinical and is entering a clinical study in patients with Yale.

• Peer-reviewed first-in-human report published in 2026.
• Patent scope extending beyond the original rare entry point.
• Preclinical work complete in the broader population, and a clinical study in patients is starting with Yale’s Center for Clinical Investigation.

A first-in-class immunology asset

A first-in-class IL-17 small molecule, generated by the same engine run in the drug-to-disease direction, on a target we did not start from. It carries its own composition-of-matter patent filing, and demonstrates that the platform is not a one-asset story.

• Novel small molecule, composition patent filed.
• Oral route, addressing demand currently served by injectable biologics.
• Engine-generated rather than licensed in.

A renal repurposing program

A repurposing program in discovery, addressing a large patient population with very limited approved options. Mechanistic validation work is underway.

• Repurposed molecule, discovery stage.
• Large population, severe unmet need.

Rare and common indications

The engine has screened more than 150 diseases and identified over ten approved assets as candidates for new indications. Programs are re-prioritised each cycle by partner readiness, population size and development path, with the strongest advancing to its next milestone.